Eugene Roussel Ph.D., M.S. , B.S.
Founder, CEO, and Chief Scientific Officer
Eugene Roussel is a founder of BioPROVAR and has served as its CEO and CSO since September 2013. After obtaining a Ph.D. in immunology, Dr. RousseI did two postdoctorals to study inflammation and then became an entrepreneur scientist and a consultant where he gained a significant amount of knowledge in biobusiness. He has published several international scientific articles, given international scientific presentations, and he is the author of 6 patents. He has taken a series of entrepreneurial business courses at Rice University and the University of Houston and an extensive course given by the USFDA in drug regulations and marketing. Working in different capacities, he has acquired a significant amount of knowledge in the field of patent laws, protein therapeutic, biotherapy, safety pharmacology, toxicology, and drug regulations. With his education, an extended expertise in inflammation and proof-of-concept data from BioTremvar, Dr. Roussel is convinced of the unique capability of BioTremvar to treat diseases induced from a deregulated primary immune response. With 20 years of experience in the biobusiness industry, the help of a network of colleagues in the field of medicine, sciences, life sciences business, and of interested peoples, Dr. Roussel strives to bring to the clinic this novel biomedicine efficient to improve the life and the chance of survival of individuals afflicted with ARDS, IBD, MS, or sepsis. Dr. Roussel and Gingras (COO) have a 20 year history of collaboration having co-authored several publications and been co-entrepreneurs of two different companies.
James Suliburk, M.D., B.S., F.A.C.S.
Chief Medical Officer
James Suliburk is a surgeon and an emergency medicine specialist treating patients every day. He is an Associate Professor at Baylor College of Medicine and an entrepreneur. Dr. Suliburk has acquired a significant expertise in the field of diseases from excess of inflammation, spending a fellowship studying the immune response of sepsis in the laboratory, publishing several scientific articles, and with over ten years of practice treating sepsis patients in the Baylor Network of Hospitals. He is a medical scientist and entrepreneur with interests in trauma research, surgery, and leveraging mobile technology to improve surgical outcomes with apps for mobile devices. Dr. Suliburk serves as the company CMO and his expertise in inflammation medicine and biobusiness provides a savvy contribution for the development of BioTremvar as a novel medicine to treat excess of inflammation diseases.